3 Dividend Winners For Your Portfolio: AstraZeneca plc, Direct Line Insurance Group plc & Tullett Prebon plc

Should you buy AstraZeneca plc (LON: AZN), Direct Line Insurance Group plc (LON: DLG) and Tullett Prebon (LON: TLPR)?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Are you looking to top up your investment portfolio, and buy some new shares? Well, how about these three companies? In this article I will debate the pros and cons of buying into a pharmaceutical firm, an insurer and a broker. Let’s start with the drugs company…

AstraZeneca

The world is getting more populous, and also more wealthy. These certain demographic trends mean that there will be a bright future for Big Pharma.

Of the drugs companies, one of my picks is AstraZeneca (LSE: AZN). What appeals to me about this business is its unerring focus on scientific research as the means to long-term profitability.

Instead of messing about with the tax rules, like Pfizer is doing, or acquiring other companies, AZ’s route to riches is innovation. And it is working. Its portfolio of anti-cancer drugs is amongst the strongest in the medical industry. And the breadth of its past winners means that it will also do well as countries such as India, China and Malaysia expand their healthcare systems.

Astra’s recent successes have already driven the share price higher, but I think there is more to come from this company. A predicted 2015 P/E ratio of 15.93, with a juicy 4.12% dividend yield means this pharma business is fairly priced, and a decent income buy.

Direct Line Group

Another high-yield star I’d like to pick is Direct Line Group (LSE: DLG), an insurance company which has been rising steadily over the past year. This is one of the most dependable companies you can think of, generating prodigious amounts of cash year-in and year-out.

Despite recent price rises, this firm is still reasonably priced, with a forecast P/E ratio of 13.00 and a dividend yield of 3.42%. The sustained and growing profitability of this business is demonstrated by the earnings per share progression:

2012: 13.42p
2013: 22.58p
2014: 25.96p
2015: 29.05p
2016: 27.62p

This is another income share to tuck away in your portfolio.

Tullett Prebon

Tullett Prebon (LSE: TLPR) is a broker which is currently in talks to takeover the broking business of its competitor ICAP.

This is a strong and highly profitable business, which will stand to gain by consolidating the interdealer broking sector. It is also keenly priced, with a P/E ratio of 9.09 and an attractive dividend yield of 4.83%, which is well covered by its profits.

Increased regulation in banking and markets is driving this consolidation, and I think Tullett could well end up as a big fish in the pond of inter-dealing broking. So this company is another of my dividend picks.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Prabhat Sakya has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Up 26% this week! Could this FTSE 250 share soar over the next year?

There could be a lot of potential in the mid-cap stocks of the FTSE 250. After a major City bank…

Read more »

Silhouette of a bull standing on top of a landscape with the sun setting behind it
Investing Articles

Can anything stop this FTSE 100 growth machine?

Even the pandemic wasn’t able to halt the progress of FTSE 100 events company Informa. But is the stock still…

Read more »

Investing Articles

Will the Rolls-Royce share price hit £6 before the New Year?

At 599.8p, the Rolls-Royce share price has come within a whisper of £6. It’s never been so high, but could…

Read more »

Smartly dressed middle-aged black gentleman working at his desk
Investing Articles

2 REITs I’m considering buying to target a long-term passive income!

REITs can be great sources of passive income over the long term. Here are a couple from the FTSE 100…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

I’m preparing for a stock market crash in 2025

Our writer explains why he's acting 'as if' there will be a stock market crash in 2025, not spending time…

Read more »

Investing Articles

Starting a Stocks and Shares ISA in 2025 could make me a millionaire. Here’s how!

Christopher Ruane outlines a couple of steps he plans to take in the coming year to boost his long-term Stocks…

Read more »

Light bulb with growing tree.
Investing Articles

Still in pennies, could the ITM Power share price hit £6 again?

A trading update from ITM Power has boosted our writer's optimism in the prospects for ITM Power despite its share…

Read more »

Senior couple crossing the road on a city street. They are walking with shopping bags while Christmas shopping.
Investing Articles

2 undervalued UK shares to consider buying before Christmas

With Christmas around the corner, the retail market is expected to enjoy a huge inflow of revenue. Here are two…

Read more »